Form 4: Teva Pharmaceutical Executive Exercises and Sells Shares to Cover Tax Obligations

Eric A. Hughes, an executive at Teva Pharmaceutical Industries, exercised restricted share units and sold a portion of the acquired shares to cover tax withholding obligations.

Summary

• On March 3, 2024, Eric A. Hughes exercised 24,900 restricted share units, each representing one ordinary share of Teva Pharmaceutical Industries.
• On March 4, 2024, Hughes sold 8,045 ordinary shares at a weighted average price of $13.3373 per share, with prices ranging from $13.25 to $13.445.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 13, 2023.
• Hughes also acquired 93,005 restricted share units on March 4, 2024, which vest annually from March 4, 2025, to March 4, 2028.
• Following these transactions, Hughes directly owns 16,855 ordinary shares and 74,701 restricted share units from a previous grant and 93,005 restricted share units from the current grant.

Sentiment

Score: 5

Explanation: The document reflects routine executive compensation activity. It doesn't indicate any significant positive or negative sentiment regarding the company's performance.

Future Outlook

The reporting person will continue to vest in restricted share units over the next four years, according to the vesting schedules outlined in the document.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often tied to compensation packages and long-term incentive plans. These transactions are closely monitored by investors for insights into management's perspective on the company's performance and future prospects.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, bonus, stock options, and restricted stock units.
• Vesting schedules for restricted stock units typically range from three to five years, aligning executive incentives with long-term shareholder value.
• Rule 10b5-1 trading plans are a common tool used by executives to manage their stock transactions while avoiding accusations of insider trading.
• Companies like Pfizer, Johnson & Johnson, and Novartis also utilize similar compensation structures for their executives.

Key Dates